Results 1 to 10 of about 24,414 (214)

Proprotein Convertase Subtilisin/Kexin Type 9 and Inflammation: An Updated Review [PDF]

Frontiers in Cardiovascular Medicine, 2022
The function of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9), a novel plasma protein, has mainly been involved in cholesterol metabolism in the liver, while, more interestingly, recent data have shown that PCSK9 also took part in the modulation ...
Na-Qiong Wu, Hui-Wei Shi, Jian-Jun Li
doaj   +4 more sources

Blockade of colon cancer metastasis via single and double silencing of PCSK7/PCSK9: enhanced T cells cytotoxicity in mouse and human [PDF]

Journal for ImmunoTherapy of Cancer
Background Immunotherapy approaches based on T cells provided breakthroughs in cancer treatment but could cause many immune-related adverse events, and their efficacy is limited for many cancers with an acquired dysfunction/exhaustion of T cells.
Delia Susan-Resiga, Nabil G Seidah, Nathalie Labrecque, Jean-Sebastien Delisle, Leila Jafarzadeh, Chloé Porcheron, Mailys Le Devehat, Anna Roubtsova, Hadi Bayat, Alexandra Evagelidis, Vatsal Sachan, Alexie Fonta Holder, Rachid Essalmani, Gabrielle Boudreau, Annik Prat, Rebecca Cusseddu, Jean-François Côté, Abdel-Majid Khatib   +17 more
doaj   +2 more sources

A molecular modeling approach for structure-based virtual screening and identification of novel anti-hypercholesterolemic agents from Grape

Informatics in Medicine Unlocked, 2022
Hypercholesterolemia is a potential cardiovascular hazard that requires immediate therapeutic intervention. Research has shown that 3-Hydroxy-3-methylglutaryl- CoA reductase (HMG CoA reductase) and Proprotein convertase subtilisin/kexin type 9 (PCSK9 ...
Precious A. Akinnusi, Samuel O. Olubode, Adebowale A. Alade, Samad A. Ahmed, Susan F. Ayekolu, Taiwo M. Ogunlade, Damilola J. Gbore, Olayemi D. Rotimi, Abigail O. Ayodele   +8 more
doaj   +1 more source

Injection of an improperly stored proprotein convertase subtilisin/kexin type 9 monoclonal antibody in a patient with secondary dyslipidemia from nephrotic syndrome: a case report

Journal of Medical Case Reports, 2023
Background Elevated plasma cholesterol and/or plasma triglyceride levels in nephrotic syndrome patients are the result of impaired lipoprotein clearance and a compensatory increase in hepatic lipoprotein synthesis. Plasma proprotein convertase subtilisin/
Tanawan Kongmalai, Nalinee Chuanchaiyakul, Yuttana Srinoulprasert, Nuntakorn Thongtang   +3 more
doaj   +1 more source

Proprotein Convertase Subtilisin Kexin 9 Inhibitors [PDF]

Cardiology Clinics, 2018
High levels of low-density lipoprotein cholesterol (LDL-C) are directly associated with an increased risk of cardiovascular disease. Reducing LDL-C levels reduces the incidence of cardiovascular events. Several lipid-lowering approaches are available to achieve the LDL-C levels recommended by current guidelines, statins being the first-line therapy ...
A. Pirillo, A. L. Catapano
openaire   +2 more sources

Proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors [PDF]

Canadian Medical Association Journal, 2019
PCSK9 is a protease that degrades hepatic LDL-C receptors. Evolocumab and alirocumab are fully human monoclonal antibodies administered as subcutaneous injections that inhibit PCSK9, preserving receptor availability to clear circulating LDL-C.[1][1],[2][2] In randomized, placebo-controlled ...
Derek, Leong, Peter E, Wu
openaire   +2 more sources

Apolipoprotein F is reduced in humans with steatosis and controls plasma triglyceride‐rich lipoprotein metabolism

Hepatology, EarlyView., 2022
Hepatic APOF transcript levels correlate inversely with plasma TG and hepatic steatosis in humans. ApoF expression in mice promotes VLDL‐TG production and lipoprotein remnant clearance in mice. Abstract Background NAFLD affects nearly 25% of the global population. Cardiovascular disease (CVD) is the most common cause of death among patients with NAFLD,
Audrey Deprince, Nathalie Hennuyer, Sander Kooijman, Amanda C. M. Pronk, Eric Baugé, Viktor Lienard, An Verrijken, Eveline Dirinck, Luisa Vonghia, Eloïse Woitrain, Niels J. Kloosterhuis, Eléonore Marez, Pauline Jacquemain, Justina C. Wolters, Fanny Lalloyer, Delphine Eberlé, Sandrine Quemener, Emmanuelle Vallez, Anne Tailleux, Mostafa Kouach, Jean‐Francois Goossens, Violeta Raverdy, Bruno Derudas, Jan Albert Kuivenhoven, Mikaël Croyal, Bart van de Sluis, Sven Francque, François Pattou, Patrick C. N. Rensen, Bart Staels, Joel T. Haas   +30 more
wiley   +1 more source

The Proprotein Convertases in Hypercholesterolemia and Cardiovascular Diseases: Emphasis on Proprotein Convertase Subtilisin/Kexin 9 [PDF]

Pharmacological Reviews, 2017
The secretory proprotein convertase (PC) family comprises nine members, as follows: PC1/3, PC2, furin, PC4, PC5/6, paired basic amino acid cleaving enzyme 4, PC7, subtilisin kexin isozyme 1/site 1 protease (SKI-1/S1P), and PC subtilisin/kexin type 9 (PCSK9).
Nabil G, Seidah, Marianne, Abifadel, Stefan, Prost, Catherine, Boileau, Annik, Prat   +4 more
openaire   +2 more sources

Serum Levels of PCSK9 Are Associated with Coronary Angiographic Severity in Patients with Acute Coronary Syndrome [PDF]

Diabetes & Metabolism Journal, 2018
BackgroundProprotein convertase subtilisin/kexin type 9 (PCSK9) is a circulating protein that promotes degradation of the low density lipoprotein receptor.
Kwi-Hyun Bae, Sung Woo Kim, Yeon-Kyung Choi, Jung Beom Seo, Namkyun Kim, Chang-Yeon Kim, Won Kee Lee, Sungwoo Lee, Jung Guk Kim, In-Kyu Lee, Jang Hoon Lee, Keun-Gyu Park   +11 more
doaj   +1 more source

Proprotein Convertase Subtilisin/Kexin 9 as a Modifier of Lipid Metabolism in Atherosclerosis

Biomedicines, 2023
Despite being the most common treatment strategy in the management of atherosclerosis and subsequent cardiovascular disease, classical statin therapy has certain disadvantages, including numerous side effects.
Anastasia V. Poznyak, Vasily N. Sukhorukov, Ilya I. Eremin, Irina I. Nadelyaeva, Nikita A. Gutyrchik, Alexander N. Orekhov   +5 more
doaj   +1 more source